Salud financiera de hoja de balance de BioNTech
Salud financiera controles de criterios 6/6
BioNTech tiene un patrimonio de los accionistas total de €20.0B y una deuda total de €2.3M, lo que sitúa su ratio deuda-patrimonio en 0.01%. Sus activos y pasivos totales son €22.3B y €2.3B respectivamente.
Información clave
0%
Ratio deuda-patrimonio
€0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | €17.30b |
| Patrimonio | €19.07b |
| Total pasivo | €3.17b |
| Activos totales | €22.24b |
Actualizaciones recientes sobre salud financiera
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05Recent updates
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (€18.3B) de BNTX superan a sus pasivos a corto plazo (€1.6B).
Pasivo a largo plazo: Los activos a corto plazo de BNTX (€18.3B) superan a sus pasivos a largo plazo (€682.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BNTX está libre de deudas.
Reducción de la deuda: BNTX no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 3%.
Cobertura de la deuda: BNTX no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: BNTX no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.